415 Capital is a specialist venture capital firm headquartered in Munich, dedicated to investing in breakthrough and life-saving medical technology innovation. The firm focuses on clinical-stage MedTech companies across cardiovascular and neurovascular disease, neuromodulation, medical robotics, and patient monitoring across Europe, the U.S., and Israel.
67% of their portfolio is in Healthcare. Their most common stage is series-b (50% of deals). Average disclosed round size is $49.1M (across 3 rounds with reported amounts).
Portfolio
5
Fund Size
$150M
Top Stage
Series B
Last 12 Mo
0
Team
HG
Hershel Groenewegen
Chief Happiness Officer
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 R3 Vascular | Series B | $87M | May 2024 |
 TRiCares | Series C | $55M | Dec 2022 |
| TRiCares | Series C | — | Sep 2022 |
 Corflow | Series B | — | — |
| CCardiac Success | Series A | $5.2M | — |
| CCorFlow Therapeutics | Series B | — | — |
Top Co-Investors
Wellington Management4 shared
Andera Partners2 shared
Karista2 shared
BioMed Ventures2 shared
Laerdal Million Lives Fund2 shared
Monte Carlo Capital2 shared
Bayern Kapital1 shared
Deerfield1 shared
Broadview Ventures1 shared
Last updated: 14 September 2026